Moderna, Inc.

Moderna is a biotechnology company focused on discovering, developing, and manufacturing medicines and vaccines powered by messenger RNA technology. Its commercial product lineup features respiratory immunizations, including Spikevax and mNEXSPIKE for COVID-19, as well as mRESVIA targeting respiratory syncytial virus. The firm organizes its pipeline across infectious diseases, oncology therapeutics, and rare disease treatments, actively evaluating candidates in late-stage clinical trials. Its products serve global populations spanning infants, high-risk individuals, and older adults, reaching patients through retail distribution, clinical healthcare settings, and government collaborations.

The enterprise operates a global manufacturing network with corporate and production facilities across the United States, the United Kingdom, Canada, and Australia, including a dedicated clinical batch supply center in Marlborough, Massachusetts. While corporate headquarters are not explicitly identified in the provided text, Moderna supplies and authorizes its medicines across more than forty international countries throughout North America, Europe, and the Asia-Pacific region.

Summary of the business section of Moderna's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“We had approximately 4,700 full-time employees in 18 countries as of December 31, 2025 .”